- Who was studied
- 17,604 adults with existing cardiovascular disease and overweight/obesity, without diabetes
- What it found
- Semaglutide 2.4 mg reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared with placebo over about 3 years.
- Important limitations
- Participants already had heart disease, so results may not apply to people at lower risk. The trial was not designed to separate weight-loss effects from other mechanisms.
- What it means for you
- This was the first trial to show a weight-loss medication directly prevents heart attacks and strokes — a major reason GLP-1s are now discussed as cardiovascular drugs, not just weight-loss drugs.